Chen · Diabetes, obesity & metabolism 2024 · systematic review and meta-analysis of randomized controlled trials · n=39 studies (2,982 participants)

Efficacy of vitamin D supplementation on glycaemic control in type 2 diabetes: An updated systematic review and meta-analysis of randomized controlled trials.

Cited 49 times in the scientific literature.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of 39 randomized controlled trials.

PubMed 39355942 · doi:10.1111/dom.15941 · record verified 2026-08-26

What was done

Authors conducted a systematic review and meta-analysis searching PubMed, EMBASE, Web of Science, and the Cochrane Library to assess the effects of vitamin D interventions on glycemic control in patients with type 2 diabetes. Outcomes analyzed included serum 25(OH)D, fasting blood glucose (FBG), HbA1c, fasting insulin, and Homeostasis Model Assessment for Insulin Resistance (HOMA-IR).

What was found

The meta-analysis included 39 randomized controlled trials with 2,982 subjects. Compared to control groups, vitamin D supplementation produced statistically significant reductions across all primary glycemic measures: - FBG: weighted mean difference (WMD) -0.49 mmol/L (95% CI: -0.69 to -0.28) - HbA1c: WMD -0.30% (95% CI: -0.43 to -0.18) - HOMA-IR: WMD -0.39 (95% CI: -0.64 to -0.14) - Fasting insulin: WMD -1.31 μIU/mL (95% CI: -2.06 to -0.56) Subgroup analyses showed effects varied by dosage, duration, baseline 25(OH)D, and BMI, with the most pronounced benefits observed with short-term, high-dose regimens in patients with baseline vitamin D deficiency, overweight status, or baseline HbA1c ≥8%.

Why it matters

This review synthesizes randomized trial evidence supporting vitamin D supplementation as an adjunctive therapy for type 2 diabetes, highlighting that clinical utility is highest in patients with existing deficiency or poor baseline glycemic control.

Limits

The abstract does not report study-level risk of bias, adverse effects, or statistical heterogeneity metrics. Absolute reductions in HbA1c were modest (0.30%), and the analysis relied on surrogate glycemic markers rather than long-term clinical or vascular outcomes.

Cited by